Project Description

Nevada Center for Biomedical Research, ME/CFS, MECFS, ME CFS, myalgic encephalomyelitis, ME, CFS, Fibromyalgia, MS, Autism, GWI, NVCBR

WPI Medical Director

Dr. Kenny De Meirleir serves as Medical Director of WPI and maintains an independent medical practice at the Clinic at WPI.

Dr. De Meirleir has extensive experience treating patients with myalgic encephalomyelitis (ME) and other chronic diseases. Much of Dr. De Meirleir’s success with his patients stems from his comprehensive treatment approach. His goal is to reduce the severity of illness through appropriate dietary changes, immune support, and specific drug treatments for chronic infectious pathogens.

Dr. De Meirleir earned his medical degree from the Vrije Universiteit Brussel in 1977, and completed an internal medicine residency in the Department of Internal Medicine, University Hospital of Vrije Universiteit Brussel. His current research focuses on a subgroup of ME patients who show evidence of chronic bacterial infection and gut dysbiosis. These patients are responding to specific antibiotic/ probiotic therapy.

For immediate assistance or to schedule an appointment call (775) 682-8504 or email Nossa Van den Vonder at

For more specific information regarding Dr. De Meirleir’s opinions and protocols view his 2014 web series,
Science for Patients presented by Wetenschap voor Patienten – ME/cvs Vereniging, here.


  • 1963 – 1969 High School Education, Koninklijk Atheneum Mechelen (Belgium)
  • 1969 – 1970 First year of pre-medical education, Memphis State University (Memphis, Tennessee, U.S.A.)
  • 1970 – 1977 Medical Education, Vrije Universiteit Brussel, Doctor in Medicine (Belgium) July 1977, Magna cum Laude
  • 1977 – 1982 Internal medicine Residency, Department of Internal Medicine, university Hospital Vrije Universiteit Brussel, under supervision of Prof. Dr. R. Six. Certification in Internal Medicine, August 1982
  • 1982 – 1984 Resident in Cardiology, Algemeen Ziekenhuis, Vrije Universiteit Brussel, under supervision of Prof. Dr. P. Block, interrupted by military service
  • 1985 Ph.D. in Physiology, July 1985


  • ECFMG Certification
  • Internal Medicine
  • Physical Education
  • Sports Medicine
  • Cardiac Rehabilitation
  • Biotechnology Techniques


  • 2014 – Presently: Emeritus Professor with teaching position, Vrije Universiteit Brussel, faculty of psychology
  • 2006 – Presently:  Medical director Himmunitas VZW (Brussels, Belgium)- volunteer
  • 2013 – Presently: Medical Director Nevada Center for Biomedical Research
  • 1985 – 2005 Director Cardiac Rehabilitation Unit, Academic Ziekenhuis Vrije Universiteit Brussel/ Universitair Ziekenhuis Brussel
  • 1985 – 2005 Consultant Department of Cardiology, Academic Ziekenhuis Vrije Universiteit Brussel/ Universitair Ziekenhuis Brussel


  • Solvay Prize
  • NATO Research Award


  1. Decreased Numbers of CD57+CD3- Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder.
    Siniscalco D, Mijatovic T, Bosmans E, Cirillo A, Kruzliak P, Lombardi VC, DE Meirleir K, Antonucci N.
    In Vivo. 2016 03-04;30(2):83-89.
  2. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.
    Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotás A, Lombardi VC.
    Transl Psychiatry. 2016 Feb 9;6:e730. doi: 10.1038/tp.2015.208.
  3. Human dendritic cells transfected with a human papilloma virus-18 construct display decreased mobility and upregulated cytokine production.
    Khaiboullina SF, Morzunov SP, Hall MR, De Meirleir KL, Rizvanov AA, Lombardi VC.
    Int J Oncol. 2013 Nov;43(5):1701-9. doi: 10.3892/ijo.2013.2074. Epub 2013 Aug 21.
  4. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Frémont M, Coomans D, Massart S, De Meirleir K.
    Anaerobe. 2013 Aug;22:50-6. doi: 10.1016/j.anaerobe.2013.06.002. Epub 2013 Jun 19.
  5. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.
    De Meirleir KL, Khaiboullina SF, Frémont M, Hulstaert J, Rizvanov AA, Palotás A, Lombardi VC.
    In Vivo. 2013 Mar-Apr;27(2):177-87.
  6. Role of psychological aspects in both chronic pain and in daily functioning in chronic fatigue syndrome: a prospective longitudinal study.
    Meeus M, Nijs J, Van Mol E, Truijen S, De Meirleir K.
    Clin Rheumatol. 2012 Jun;31(6):921-9. doi: 10.1007/s10067-012-1946-z. Epub 2012 Feb 16.
  7. Myalgic encephalomyelitis: International Consensus Criteria.
    Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S.
    J Intern Med. 2011 Oct;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x. Epub 2011 Aug 22. Review.
  8. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro.
    Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayr A, Ablashi D, Lund TC, Tolar J, De Meirleir K, Montoya JG, Komaroff AL, Ambros PF, Medveczky PG.
    Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5563-8. doi: 10.1073/pnas.0913586107. Epub 2010 Mar 8.
  9. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome.
    Sheedy JR, Wettenhall RE, Scanlon D, Gooley PR, Lewis DP, McGregor N, Stapleton DI, Butt HL, DE Meirleir KL.
    In Vivo. 2009 Jul-Aug;23(4):621-8.
  10. Severe versus Moderate criteria for the new pediatric case definition for ME/CFS.
    Jason L, Porter N, Shelleby E, Till L, Bell DS, Lapp CW, Rowe K, De Meirleir K.
    Child Psychiatry Hum Dev. 2009 Dec;40(4):609-20. doi: 10.1007/s10578-009-0147-8. Epub 2009 Jun 10.
  11. A comparison of patients with chronic fatigue syndrome in two “ideologically” contrasting clinics.
    Van Houdenhove B, Van Hoof E, Becq K, Kempke S, Luyten P, De Meirleir K.
    J Nerv Ment Dis. 2009 May;197(5):348-53. doi: 10.1097/NMD.0b013e3181a2081f.
  12. Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients.
    Frémont M, Metzger K, Rady H, Hulstaert J, De Meirleir K.
    In Vivo. 2009 Mar-Apr;23(2):209-13.
  13. Exercise performance and chronic pain in chronic fatigue syndrome: the role of pain catastrophizing.
    Nijs J, Van de Putte K, Louckx F, Truijen S, De Meirleir K.
    Pain Med. 2008 Nov;9(8):1164-72. Epub 2007 Oct 3.
  14. Lower frequency of IL-17F sequence variant (His161Arg) in chronic fatigue syndrome patients.
    Metzger K, Frémont M, Roelant C, De Meirleir K.
    Biochem Biophys Res Commun. 2008 Nov 7;376(1):231-3. doi: 10.1016/j.bbrc.2008.08.135. Epub 2008 Sep 5.
  15. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance.
    Meeus M, Nijs J, McGregor N, Meeusen R, De Schutter G, Truijen S, Frémont M, Van Hoof E, De Meirleir K.
    In Vivo. 2008 Jan-Feb;22(1):115-21.
  16. Comparison of two exercise testing protocols in patients with chronic fatigue syndrome.
    Nijs J, Zwinnen K, Meeusen R, de Geus B, De Meirleir K.
    J Rehabil Res Dev. 2007;44(4):553-9.
  17. Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome.
    Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K.
    Am J Med Sci. 2007 Feb;333(2):78-84.
  18. Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications.
    Nijs J, Meeus M, De Meirleir K.
    Man Ther. 2006 Aug;11(3):187-91. Epub 2006 Jun 14. Review.
  19. Generalized joint hypermobility is more common in chronic fatigue syndrome than in healthy control subjects.
    Nijs J, Aerts A, De Meirleir K.
    J Manipulative Physiol Ther. 2006 Jan;29(1):32-9.
  20. Double-stranded RNA-dependent protein kinase (PKR) is a stress-responsive kinase that induces NFkappaB-mediated resistance against mercury cytotoxicity.
    Frémont M, Vaeyens F, Herst CV, De Meirleir KL, Englebienne P.
    Life Sci. 2006 Mar 13;78(16):1845-56. Epub 2005 Dec 1
  21. Employment status in chronic fatigue syndrome. A cross-sectional study examining the value of exercise testing and self-reported measures for the assessment of employment status.
    Nijs J, Van de Putte K, Louckx F, De Meirleir K.
    Clin Rehabil. 2005 Dec;19(8):895-9.
  22. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome.
    Nijs J, De Meirleir K.
    In Vivo. 2005 Nov-Dec;19(6):1013-21. Review.
  23. Chronic fatigue syndrome: exercise performance related to immune dysfunction.
    Nijs J, Meeus M, McGregor NR, Meeusen R, de Schutter G, van Hoof E, de Meirleir K.
    Med Sci Sports Exerc. 2005 Oct;37(10):1647-54.
  24. Nitric oxide and chronic fatigue syndrome: Are we caring for our patients or are we practicing selfcare?
    Nijs J, De Meirleir K.
    Med Hypotheses. 2006;66(2):449-50. Epub 2005 Oct 10. No abstract available.
  25. 37-Kilodalton/83-kilodalton RNase L isoform ratio in peripheral blood mononuclear cells: analytical performance and relevance for chronic fatigue syndrome.
    Frémont M, Vaeyens F, Herst CV, De Meirleir K, Englebienne P.
    Clin Diagn Lab Immunol. 2005 Oct;12(10):1259-60; author reply 1260. No abstract available.
  26. The Chronic Fatigue Syndrome Activities and Participation Questionnaire (CFS-APQ): an overview.
    Nijs J, Vaes P, De Meirleir K.
    Occup Ther Int. 2005;12(2):107-21.
  27. 2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.
    Frémont M, El Bakkouri K, Vaeyens F, Herst CV, De Meirleir K, Englebienne P.
    Exp Mol Pathol. 2005 Jun;78(3):239-46. Epub 2005 Mar 2.
  28. Oxidative stress might reduce essential fatty acids in erythrocyte membranes of chronic fatigue syndrome patients.
    Nijs J, De Meirleir K.
    Nutr Neurosci. 2004 Aug;7(4):251-3. No abstract available.
  29. Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation?
    Nijs J, Van de Velde B, De Meirleir K.
    Med Hypotheses. 2005;64(3):558-62.
  30. Prediction of peak oxygen uptake in patients fulfilling the 1994 CDC criteria for chronic fatigue syndrome.
    Nijs J, De Meirleir K.
    Clin Rehabil. 2004 Nov;18(7):785-92.
  31. Kinesiophobia in chronic fatigue syndrome: assessment and associations with disability.
    Nijs J, De Meirleir K, Duquet W.
    Arch Phys Med Rehabil. 2004 Oct;85(10):1586-92.
  32. Norandrosterone and noretiocholanolone concentration before and after submaximal standardized exercise.
    de Geus B, Delbeke F, Meeusen R, Van Eenoo P, De Meirleir K, Busschaert B.
    Int J Sports Med. 2004 Oct;25(7):528-32.
  33. Chronic fatigue syndrome: lack of association between pain-related fear of movement and exercise capacity and disability.
    Nijs J, Vanherberghen K, Duquet W, De Meirleir K.
    Phys Ther. 2004 Aug;84(8):696-705.
  34. Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response.
    Nijs J, De Meirleir K, Meeus M, McGregor NR, Englebienne P.
    Med Hypotheses. 2004;62(5):759-65.
  35. Disability evaluation in chronic fatigue syndrome: associations between exercise capacity and activity limitations/participation restrictions.
    Nijs J, De Meirleir K, Wolfs S, Duquet W.
    Clin Rehabil. 2004 Mar;18(2):139-48.
  36. Hormonal responses during prolonged exercise are influenced by a selective DA/NA reuptake inhibitor.
    Piacentini MF, Meeusen R, Buyse L, De Schutter G, De Meirleir K.
    Br J Sports Med. 2004 Apr;38(2):129-33.
    PMID: 15039245 Free PMC Article
  37. Atypical depression as a secondary symptom in chronic fatigue syndrome.
    Van Hoof E, Cluydts R, De Meirleir K.
    Med Hypotheses. 2003 Jul;61(1):52-5.
  38. Psychometric properties of the Dutch Chronic Fatigue Syndrome–Activities and Participation Questionnaire (CFS-APQ).
    Nijs J, Vaes P, McGregor N, Van Hoof E, De Meirleir K.
    Phys Ther. 2003 May;83(5):444-54.
  39. Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome.
    Nijs J, De Becker P, De Meirleir K, Demanet C, Vincken W, Schuermans D, McGregor N.
    Chest. 2003 Apr;123(4):998-1007.
  40. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue.
    Englebienne P, Verhas M, Herst CV, De Meirleir K.
    Med Hypotheses. 2003 Feb;60(2):175-8
  41. Chronic fatigue syndrome: a risk factor for osteopenia?
    Nijs J, De Meirleir K, Englebienne P, McGregor N.
    Med Hypotheses. 2003 Jan;60(1):65-8.
  42. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients.
    Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K.
    FEMS Immunol Med Microbiol. 2002 Nov 15;34(3):209-14.
  43. No effect of a noradrenergic reuptake inhibitor on performance in trained cyclists.
    Piacentini MF, Meeusen R, Buyse L, De Schutter G, Kempenaers F, Van Nijvel J, De Meirleir K.
    Med Sci Sports Exerc. 2002 Jul;34(7):1189-93.
  44. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients.
    Demettre E, Bastide L, D’Haese A, De Smet K, De Meirleir K, Tiev KP, Englebienne P, Lebleu B.
    J Biol Chem. 2002 Sep 20;277(38):35746-51. Epub 2002 Jul 12.
  45. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome.
    Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ.
    J Interferon Cytokine Res. 2002 Apr;22(4):443-56.
  46. Antiviral pathway activation in chronic fatigue syndrome and acute infection.
    De Meirleir K, Suhadolnik RJ, Lebleu B, Englebienne P.
    Clin Infect Dis. 2002 May 15;34(10):1420-1; author reply 1421-2. No abstract available.
  47. Brain microdialysis in exercise research.
    Meeusen R, Piacentini MF, De Meirleir K.
    Sports Med. 2001;31(14):965-83. Review.
  48. A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome.
    De Becker P, McGregor N, De Meirleir K.
    J Intern Med. 2001 Sep;250(3):234-40.
  49. Effect of exercise on portal vein blood flow in man.
    Rehrer NJ, Smets A, Reynaert H, Goes E, De Meirleir K.
    Med Sci Sports Exerc. 2001 Sep;33(9):1533-7.
  50. Exercise performance is not influenced by a 5-HT reuptake inhibitor.
    Meeusen R, Piacentini MF, Van Den Eynde S, Magnus L, De Meirleir K.
    Int J Sports Med. 2001 Jul;22(5):329-36.
  51. How significant are primary sleep disorders and sleepiness in the chronic fatigue syndrome?
    Le Bon O, Fischler B, Hoffmann G, Murphy JR, De Meirleir K, Cluydts R, Pelc I.
    Sleep Res Online. 2000;3(2):43-8.
  52. Exercise capacity in chronic fatigue syndrome.
    De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K.
    Arch Intern Med. 2000 Nov 27;160(21):3270-7. Erratum in: Arch Intern Med 2001 Sep 10;161(16):2051-2.
  53. Relationship between muscle T2* relaxation properties and metabolic state: a combined localized 31P-spectroscopy and 1H-imaging study.
    Vandenborne K, Walter G, Ploutz-Snyder L, Dudley G, Elliott MA, De Meirleir K.
    Eur J Appl Physiol. 2000 May;82(1-2):76-82.
  54. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome.
    De Meirleir K, Bisbal C, Campine I, De Becker P, Salehzada T, Demettre E, Lebleu B.
    Am J Med. 2000 Feb;108(2):99-105.
  55. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome.
    De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B.
    Horm Metab Res. 1999 Jan;31(1):18-21.
  56. The influence of cold and compression on lymph flow at the ankle.
    Meeusen R, van der Veen P, Joos E, Roeykens J, Bossuyt A, De Meirleir K.
    Clin J Sport Med. 1998 Oct;8(4):266-71.
  57. Autonomic testing in patients with chronic fatigue syndrome.
    De Becker P, Dendale P, De Meirleir K, Campine I, Vandenborne K, Hagers Y.
    Am J Med. 1998 Sep 28;105(3A):22S-26S.
  58. Validity and reliability in a Flemish population of the WHO-MONICA Optional Study of Physical Activity Questionnaire.
    Roeykens J, Rogers R, Meeusen R, Magnus L, Borms J, de Meirleir K.
    Med Sci Sports Exerc. 1998 Jul;30(7):1071-5.
  59. Blood ammonia–heart rate relationship during graded exercise is not influenced by glycogen depletion.
    Roeykens J, Magnus L, Rogers R, Meeusen R, De Meirleir K.
    Int J Sports Med. 1998 Jan;19(1):26-31.
  60. Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist.
    Meeusen R, Roeykens J, Magnus L, Keizer H, De Meirleir K.
    Int J Sports Med. 1997 Nov;18(8):571-7
  61. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.
    Suhadolnik RJ, Peterson DL, O’Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W.
    J Interferon Cytokine Res. 1997 Jul;17(7):377-85.
  62. Generalized anxiety disorder in chronic fatigue syndrome.
    Fischler B, Cluydts R, De Gucht Y, Kaufman L, De Meirleir K.
    Acta Psychiatr Scand. 1997 May;95(5):405-13.
  63. Physical fatigability and exercise capacity in chronic fatigue syndrome: association with disability, somatization and psychopathology.
    Fischler B, Dendale P, Michiels V, Cluydts R, Kaufman L, De Meirleir K.
    J Psychosom Res. 1997 Apr;42(4):369-78.
  64. Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study.
    Meeusen R, Smolders I, Sarre S, de Meirleir K, Keizer H, Serneels M, Ebinger G, Michotte Y.
    Acta Physiol Scand. 1997 Apr;159(4):335-41.
  65. Sleep anomalies in the chronic fatigue syndrome. A comorbidity study.
    Fischler B, Le Bon O, Hoffmann G, Cluydts R, Kaufman L, De Meirleir K.
    Neuropsychobiology. 1997;35(3):115-22.
  66. Effects of tryptophan and/or acute running on extracellular 5-HT and 5-HIAA levels in the hippocampus of food-deprived rats.
    Meeusen R, Thorré K, Chaouloff F, Sarre S, De Meirleir K, Ebinger G, Michotte Y.
    Brain Res. 1996 Nov 18;740(1-2):245-52.
  67. Cognitive functioning in patients with chronic fatigue syndrome.
    Michiels V, Cluydts R, Fischler B, Hoffmann G, Le Bon O, De Meirleir K.
    J Clin Exp Neuropsychol. 1996 Oct;18(5):666-77.
  68. Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow.
    Fischler B, D’Haenen H, Cluydts R, Michiels V, Demets K, Bossuyt A, Kaufman L, De Meirleir K.
    Neuropsychobiology. 1996;34(4):175-83.
  69. Exercise and brain neurotransmission.
    Meeusen R, De Meirleir K.
    Sports Med. 1995 Sep;20(3):160-88. Review.
  70. Energy-rich phosphates in slow and fast human skeletal muscle.
    Vandenborne K, Walter G, Ploutz-Snyder L, Staron R, Fry A, De Meirleir K, Dudley GA, Leigh JS.
    Am J Physiol. 1995 Apr;268(4 Pt 1):C869-76.
  71. No influence of ACTH on maximal performance.
    Soetens E, De Meirleir K, Hueting JE.
    Psychopharmacology (Berl). 1995 Apr;118(3):260-6.
  72. An early effect of acute plasma volume expansion in humans on serum erythropoietin concentration.
    Szyguła Z, Smitz J, Roeykens J, De Meirleir K, Klausen T.
    Eur J Appl Physiol Occup Physiol. 1995;72(1-2):106-10.
  73. Ectopic atrial tachycardia in a young athlete.
    Dendale P, De Meirleir K, De Wolf D.
    Med Sci Sports Exerc. 1994 Aug;26(8):937-40.
  74. 31P magnetic resonance muscle spectroscopy in fibromyalgia.
    Joos E, De Meirleir K, Vandenborne K, Neirinck P.
    J Rheumatol. 1993 Nov;20(11):1985-6. No abstract available.
  75. 1H editing of 2-deuterated exogenous and natural endogenous D-glucose in biological samples.
    Biesemans M, Kayser F, Van Cauteren M, Rehrer NJ, Neirinck P, de Meirleir K, Malaisse WJ, Willem R.
    Magn Reson Med. 1993 Jul;30(1):120-3.
  76. Exercise changes in plasma tryptophan fractions and relationship with prolactin.
    Fischer HG, Hollmann W, De Meirleir K.
    Int J Sports Med. 1991 Oct;12(5):487-9.
  77. 31P-NMR spectroscopy and the metabolic properties of different muscle fibers.
    Achten E, Van Cauteren M, Willem R, Luypaert R, Malaisse WJ, Van Bosch G, Delanghe G, De Meirleir K, Osteaux M.
    J Appl Physiol (1985). 1990 Feb;68(2):644-9.
  78. Prevalence of ventricular premature beats during stress testing in patients with exercise hypertension and the association with a positive family history of established hypertension.
    Dendale P, De Meirleir K.
    Eur Heart J. 1989 Jul;10(7):666-9.
  79. A new look to the andropause: altered function of the gonadotrophs.
    Vermeulen A, Deslypere JP, De Meirleir K.
    J Steroid Biochem. 1989 Jan;32(1B):163-5.
  80. [The behavior of arterial blood pressure in dynamic and static muscle exercise with respect to atrial natriuretic peptide and neurotransmitters].
    Hollmann W, Völker K, Heck H, Rost R, De Meirleir K.
    Z Kardiol. 1989;78 Suppl 7:211-9. Review. German
  81. Stress, physical activity and hypertension.
    De Meirleir K, Buyens G, Cooman H, Block P.
    Acta Cardiol Suppl. 1988;29:29-36. Review. No abstract available.
  82. Automated micro-method for determining L-(+)-lactate in arterialized whole blood.
    Gerlo E, Gorus F, De Meirleir K.
    Clin Chem. 1987 Jan;33(1):188-9. No abstract available.
  83. Cardiovascular effects of extreme physical training.
    Hollmann W, Rost R, De Meirleir K, Liesen H, Heck H, Mader A.
    Acta Med Scand Suppl. 1986;711:193-203.
  84. Beta-endorphin and ACTH levels in peripheral blood during and after aerobic and anaerobic exercise.
    de Meirleir K, Naaktgeboren N, Van Steirteghem A, Gorus F, Olbrecht J, Block P.
    Eur J Appl Physiol Occup Physiol. 1986;55(1):5-8.
  85. Evidence for serotoninergic control of exercise-induced prolactin secretion.
    De Meirleir K, L’Hermite-Balériaux M, L’Hermite M, Rost R, Hollmann W.
    Horm Metab Res. 1985 Jul;17(7):380-1. No abstract available.
  86. Exercise-induced prolactin release is related to anaerobiosis.
    De Meirleir KL, Baeyens L, L’Hermite-Baleriaux M, L’Hermite M, Hollmann W.
    J Clin Endocrinol Metab. 1985 Jun;60(6):1250-2.
  87. Pergolide mesylate inhibits exercise-induced prolactin release in man.
    De Meirleir K, Baeyens L, L’Hermite M, L’Hermite-Balériaux M, Olbrecht J, Holmann W.
    Fertil Steril. 1985 Apr;43(4):628-31.
  88. The role of endogenous opiates in thermal regulation of the body during exercise.
    De Meirleir K, Arentz T, Hollmann W, Vanhaelst L.
    Br Med J (Clin Res Ed). 1985 Mar 9;290(6470):739-40.
  89. Bronchogenic carcinoma: a rare cause of nontraumatic pneumopericardium.
    Rongé R, Roels P, De Meirleir K, Schandevyl W, Dewilde P, Block P.
    Acta Cardiol. 1983;38(6):565-9.
  90. Myocardial sarcoidosis: a rare cause for ventricular aneurysm.
    De Meirleir K.
    Acta Cardiol. 1982;37(1):53-8. No abstract available.
  91. Bronchodilating effect on mexiletine.
    De Meirleir K, Vincken W.
    Ann Intern Med. 1980 Oct;93(4):640. No abstract available.
  92. Hypothyroidism with normal thyroid hormone levels as a consequence of autoimmune thyroiditis and peripheral resistance to thyroid hormone.
    De Meirleir K, Golstein J, Jonckheer MH, Vanhaelst L.
    Acta Clin Belg. 1980;35(2):107-9. No abstract available.